InflaRx N.V. (IFRX) vs Protalix BioTherapeutics, Inc. (PLX)
- InflaRx N.V. IFRX 1.32 −8.33%
- Protalix BioTherapeutics, Inc. PLX 2.62 −2.96%
InflaRx N.V. and Protalix BioTherapeutics, Inc. are both Biotechnology companies. InflaRx N.V. and Protalix BioTherapeutics, Inc. are of similar size ($217.5M and $212.2M). InflaRx N.V. has negative trailing earnings, so its P/E is not meaningful; Protalix BioTherapeutics, Inc. trades at 10.9×. Protalix BioTherapeutics, Inc. grew revenue faster over the last twelve months: 30.1% against −83.4%. Protalix BioTherapeutics, Inc. has the higher net margin (23.5% vs 0.00%) and the higher return on invested capital (48.5% vs 0.00%). Across the 17 metrics below, Protalix BioTherapeutics, Inc. leads on 11 and InflaRx N.V. on 6.
Valuation
Profitability
| Metric | IFRX | PLX | Biotechnology median |
|---|---|---|---|
| Gross margin | (26,762.42%) | 69.20% | 65.16% |
| Operating margin | 0.00% | 28.89% | 0.00% |
| Net margin | 0.00% | 23.50% | 0.00% |
| Free cash flow margin | 0.00% | 9.51% | 0.00% |
| Return on equity | (38.71%) | 31.23% | (56.36%) |
| Return on assets | (32.75%) | 20.07% | (48.04%) |
| Return on invested capital | 0.00% | 48.48% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack